DANTE-LABS
10.10.2019 12:13:07 CEST | Business Wire | Press release
Dante Labs announced today the official launch of its premium 2-week turnaround time for its whole genome sequencing tests. On average, genetics labs in Europe, Asia and the United States offer turnaround times between six to ten weeks, and just for the raw data. Dante Labs offers reports and raw data within two weeks from receiving the sample back.
The new service is possible thanks to the new Illumina-backed, high-throughput, automated sequencing centre that Dante Labs built in Italy, fully dedicated to the classical Whole Genome and the WholeGenomeZ™ sequencing tests.
“It is a huge difference to have our own sequencing centre.” Dante Labs CEO Andrea Riposati says. “We thought we could offer best in class service by externalizing the sequencing to third party labs. Through our initial model, thousands of people received their full whole genome results at affordable prices, receiving a full picture of their DNA for the first time in their life, often after years of guessing and after life-long undiagnosed odysseys. However, in the last twelve months about 20% of our users experienced delays – in some cases significant ones – because of delays from third party labs. Now, we can go from being criticized as ‘too slow’ to providing first-class sequencing speed matched with the first-class quality of our sequencing lab. If someone needs an urgent whole genome sequencing, we are the go-to-company.”
In order to ensure everyone received results on time and is also fully aware of the status of its samples, Dante Labs made significant investments in the last four months:
- Dante Labs built its own high-throughput sequencing center in L’Aquila, Italy, a 900-square meter GDPR-compliant, certified facility;
- Dante Labs fully internalized its non-US logistics in Italy and selected a new, best-in-class fulfilment partner in North America;
- Dante Labs developed a clearer messaging system to alert individuals about the status of their samples, including visual widgets and smart automated emails, personalized for family members who registered multiple kits and ordered multiple reports;
The price of the Premium Whole Genome is €899 (or $949) for the fast turnaround time vs. €599 (or $649) for the standard turnaround time. The price for the Super Premium WholeGenomeZ is €1399 (or $1499) for the fast turnaround time, and €899 (or $999) for the standard turnaround time.
These prices are still way below what individuals are forced to pay by offline labs across Europe, North America, South America, Oceania and Asia.
About Dante Labs
Dante Labs is global genetic testing and data analysis company specialized in whole genome sequencing and interpretation. To learn more or to purchase a Dante Labs whole genome sequencing test, visit www.dantelabs.com and follow @DanteLabs , or visit our YouTube Channel .
View source version on businesswire.com: https://www.businesswire.com/news/home/20191010005388/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 01:01:00 CEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
FDA Authorizes ZYN ULTRA Nicotine Pouches Following Scientific Review21.8.2026 21:11:00 CEST | Press release
Authorizations add selection of ZYN ULTRA products to PMI U.S.’s growing portfolio of better alternatives for legal-age adults who smoke or use traditional oral tobacco products Philip Morris International Inc. (NYSE: PM) today announces that the U.S. Food and Drug Administration (FDA) issued Marketing Granted Orders to PMI’s U.S. affiliate, Swedish Match USA, Inc., authorizing the marketing of 11 ZYN ULTRA moist oral nicotine pouch products, including all 9mg variants and one 11mg variant. Additional 11mg variants remain under scientific review. Today’s action further enhances PMI’s leadership role in the smoke-free category. “We are delighted with the FDA’s decision to authorize a range of ZYN ULTRA products, which will build on ZYN’s position as America’s leading smoke-free product brand,” said Stacey Kennedy, PMI U.S. CEO. “We look forward to expanding our portfolio of better choices for the 45 million Americans who consume nicotine products.” ZYN ULTRA positions the brand to furth
58% of Consumers Say They Don't Care Whether a Product is a National Brand or Private Label. They Just Buy What They Need21.8.2026 12:00:00 CEST | Press release
New NIQ & World Data Lab report reveals how consumer polarization is redefining value, accelerating private label adoption, and reshaping competition on the shelf As fast-moving consumer goods (FMCG) prices rose 26% globally between 2021 and 2025, consumers have become more deliberate about where they save and where they spend. NielsenIQ (NYSE: NIQ) has released new findings showing that private label is no longer viewed simply as a lower-cost substitute, but as a credible competitor across value, mainstream, and premium segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260819950224/en/ Private label is no longer just a value play. The findings, published in NIQ’s latest report, A Tale of Two Consumers: The Polarized Mindsets Reshaping Global Consumption, created in collaboration with World Data Lab, show how consumer polarization is redefining value and reshaping competition on the shelf. The report also draws on ins
Tanium Reappoints Co-Founder Orion Hindawi as CEO to Drive Next Chapter of Growth20.8.2026 21:10:00 CEST | Press release
Company to focus on deepening its Autonomous IT capabilities, further expanding AI offerings across its portfolio, and strengthening customer and partner engagement Tanium, a leader in Autonomous IT, today announced that Co-Founder and Executive Chairman Orion Hindawi has been appointed Chief Executive Officer, effective immediately. Dan Streetman is stepping down as CEO and as a member of the Board after leading Tanium for the last three years, during which time Tanium scaled its go-to-market operations and secured strong industry analyst recognition for innovation within the Tanium platform. Streetman will continue to advise Tanium as part of the transition and co-founder David Hindawi will return to the role of Chairman of the Board. With this foundation in place, this transition positions Tanium to deepen its Autonomous IT capabilities and further expand AI offerings across its portfolio and strengthen customer and partner engagement. The Hindawis co-founded Tanium in 2007 to build
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom